Alzinova AB’s Post

Exciting times in Alzheimer's research! 🧠   The authorization of several drugs for treating Alzheimer's is a positive step forward for the field. At Alzinova AB, we're proud to contribute to this momentum with our unique approach.   Our vaccine specifically targets oligomers, the toxic proteins implicated in Alzheimer's, setting us apart in the fight against this devastating disease. With great results supporting the potential for our innovative solution, we're excited about the future. #AlzheimersResearch #Innovation #Healthcare #Neuroscience #FutureOfMedicine

We want to take a moment and say thank you! At Alzinova AB, we're incredibly grateful for all of you that supports us, your belief in our work and for being part of our journey. Together, we can make a difference in Alzheimer’s. #AlzheimersResearch #TogetherWeCan #Alzinova

Continued progress in our phase 1b study!   We are pleased to announce that we have taken an important step in our ongoing phase 1b study with the vaccine candidate ALZ-101 as we have successfully dosed all patients with the first dose in the high-dose cohort.   This phase of the study involves administering ALZ-101 four times over a 16-week period to six patients, followed by a four-week monitoring phase. The purpose of the high-dose cohort is to evaluate a higher dose of the vaccine candidate ALZ-101 ahead of an upcoming clinical phase 2 study.   "The fact that we have now dosed all patients with the first dose in the high-dose cohort of our phase 1b study is another significant step forward in the development of our vaccine candidate ALZ-101. We look forward to presenting the results in the fourth quarter of 2024 and continuing our work for an effective treatment against Alzheimer's disease," comments Kristina Torfgård, CEO of Alzinova AB.   We plan to present data from this high-dose cohort in the fourth quarter of 2024.   All the details can be found in the press release – link in the comments.   #ClinicalDevelopment #AlzheimerResearch

Last week, we announced that we will be presenting data from our phase 1b study of the vaccine candidate ALZ-101 at the prestigious Alzheimer's Association International Conference (AAIC) 2024! Henrik Zetterberg, professor of neurochemistry and our esteemed scientific advisor to Alzinova AB, will present the abstract titled "Phase 1b trial on the safety, tolerability and immunogenicity of anti-amyloid vaccine ALZ-101 in subjects with MCI or mild AD." Read more in the press release, link in comments. #AlzheimersResearch #AAIC2024 #Biotech 

📢 Exciting News from Alzinova AB! 📢   We are thrilled to announce that we have successfully completed the rights issue of shares, as resolved by the Board of Directors on April 26, 2024. We are proud to share that the total subscription rate stands at approximately 106.2 percent, and thus making the Rights Issue oversubscribed.   This success means that Alzinova will receive approximately SEK 34.4 million before issue costs, and no underwriting commitments will be utilized.   “I would like to extend a big thank you to both our existing and new shareholders for the trust we have received. The oversubscription of the Rights Issue is a sign of strength that confirms the great interest in Alzinova. We have now secured financing to complete the clinical phase 1b study with our drug candidate ALZ-101, further prepare for phase 2 clinical development, and thereby optimize the company's position for future partnerships. We now look forward to continuing our development to create long-term shareholder value and enable patients to live independent and active lives free from the impact of Alzheimer's disease.", says CEO Kristina Torfgård.   Thank you to all our shareholders for your continued trust and support. Together, we are one step closer to our mission of combating Alzheimer's disease.   To read the full press release, click on the links in the comment section.   #Biotechnology #RightsIssue #Investment #Innovation

Our CEO Kristina Torfgård recently delivered an insightful presentation (in Swedish) at Aktiespararna, sharing the latest advancements and future plans for Alzinova. The presentation is available on our website for those of you that couldn’t join us live.   Don't miss out on this opportunity to stay informed about our progress and vision. Visit Alzinova AB's website to watch the full presentation now, link below!   #Biotech #AlzheimerResearch #CompanyUpdate

We had a successful visit to US BIO in June. Alzinova AB's Business Development Director, Sebastian Hansson, presented positive data from our phase 1b study with ALZ-101 to key players in Big Pharma.   "These kinds of events are important for us when we work with partnering. It gives us a good opportunity to meet key contacts and advance the process. It was clear that Alzheimer's in particular was seen as the next big trend with great potential for new blockbusters.", says Sebastian Hansson.   Exciting times lie ahead as we forge ahead in our mission.   #Biotech #AlzheimersResearch #Partnerships #Healthcare

We are pleased to announce a new positive safety review for our phase 1b clinical trial of ALZ-101! The independent Data Safety Monitoring Board (DSMB) has given us the green light to continue as planned, reaffirming the safety and tolerability of our vaccine candidate.   This review covered both the extension part (B part) and the high-dose part (A2 part) of the study. With no safety concerns, we are on track to gather vital data for our upcoming phase 2 study.   Kristina Torfgård, CEO of Alzinova AB, shared, "We are pleased with the continued positive response from the independent expert group and that there are no obstacles from a safety perspective to conduct these parts of the study. We look forward to data from part A2 and also data from part B in the autumn of 2024 which will give us a more comprehensive picture of the vaccine candidate's immune response, which is strategically important for the phase 2 study."   Read the full press release, link in comments.   #ClinicalTrials #BioTech #AlzheimersResearch

🔬 Alzheimer's disease is the most common form of dementia, accounting for between 60 and 70 per cent of all cases. Cases of the disease are increasing as we get older, and the consequences for both patients and their families are significant. Treatment options are currently insufficient.   🚀 Alzinova is working to change this. Alzinova AB's CEO, Kristina Torfgård, recently presented the company's exciting research results, the way forward, and the ongoing rights issue at BioStock - Connecting Innovation and Capital.   Watch the presentation (in Swedish) and learn more about our progress in the fight against Alzheimer's disease, link in comments.   #Alzheimers #Research #Biotech #Health #Innovation